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Hyaluronan is made and extruded from cells to form a pericellular or extracellular matrix
(ECM) and is present in virtually all tissues in the body. The size and form of hyaluronan
present in tissues are indicative of a healthy or inflamed tissue, and the interactions of
hyaluronan with immune cells can influence their response. Thus, in order to understand
how inflammation is regulated, it is necessary to understand these interactions and their
consequences. Although there is a large turnover of hyaluronan in our bodies, the large
molecular mass form of hyaluronan predominates in healthy tissues. Upon tissue damage
and/or infection, the ECM and hyaluronan are broken down and an inflammatory response
ensues. As inflammation is resolved, the ECM is restored, and high molecular mass hyaluro-
nan predominates again. Immune cells encounter hyaluronan in the tissues and lymphoid
organs and respond differently to high and low molecular mass forms. Immune cells differ
in their ability to bind hyaluronan and this can vary with the cell type and their activation
state. For example, peritoneal macrophages do not bind soluble hyaluronan but can be
induced to bind after exposure to inflammatory stimuli. Likewise, naïve T cells, which typ-
ically express low levels of the hyaluronan receptor, CD44, do not bind hyaluronan until
they undergo antigen-stimulated T cell proliferation and upregulate CD44. Despite sub-
stantial knowledge of where and when immune cells bind hyaluronan, why immune cells
bind hyaluronan remains a major outstanding question. Here, we review what is currently
known about the interactions of hyaluronan with immune cells in both healthy and inflamed
tissues and discuss how hyaluronan binding by immune cells influences the inflammatory
response.
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INTRODUCTION
The function of our immune cells is to maintain homeostasis.
When immune cells detect damage or infection, they respond by
making an inflammatory response that is aimed at removing the
threat. The ultimate goal is to repair the damage and return the
tissue to its original state. The inflammatory process is a potent,
fundamental, and normally protective immune mechanism. How-
ever, if it is not properly regulated, it can result in serious damage
to the host and lead to a pathological state. In fact, inflammation
is thought to be at the root of many chronic conditions, from
heart attacks and strokes to arthritis and type-2 diabetes. Thus,
it is important to understand the factors that drive and resolve
inflammation in order to better treat inflammatory diseases and
identify novel therapeutic targets and new predictors of treatment
efficacy.
Our skin and mucosal surfaces provide the first line of
defense, and any pathogen that breaches these barriers activates
innate immune cells, which trigger an inflammatory response.
Macrophages are innate immune cells that reside in our tissues
and play a key role in maintaining tissue homeostasis. Their pri-
mary role is to remove dead and damaged cells, and to detect
and destroy invading pathogens. Dendritic cells are also innate
immune cells that become activated in response to pathogens
and migrate to the lymph node to activate antigen-specific adap-
tive immune cells (T and B lymphocytes). Once the pathogen
and cell debris are removed, damaged cells and extracellular
matrix (ECM) components are replaced, and tissue homeosta-
sis is restored. One major constituent of the ECM is hyaluronan
(HA), a large glycosaminoglycan under physiological conditions
that becomes fragmented during infection and tissue damage, and
is restored upon the resolution of inflammation. HA turnover is
perturbed during inflammation and HA fragments accumulate
extracellularly. These fragments are associated with propagating
the inflammatory response, whereas full-length high molecular
mass HA is associated with the resolution of inflammation. While
all immune cells express the HA receptor, CD44, not many bind
HA under homeostatic conditions. However, this changes when
immune cells become activated. In this review, we discuss what
is known about the interactions between immune cells and HA
during homeostasis and inflammation.
HA TURNOVER DURING HOMEOSTASIS AND
INFLAMMATION
HA is widely distributed throughout all the tissues in the body with
up to 50% being present in the skin. HA is found at high levels in
the umbilical cord (~4 mg/ml) and synovial fluid (~2 mg/ml); it is
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prevalent in the vitreous of the eye (~100–400µg/g of wet tissues)
and the dermis of the skin (~500µg/g wet tissue); and present at
10–100 ng/ml in the blood (1, 2). It is hygroscopic in nature and
has viscoelastic properties making it a useful lubricant in joints.
HA comprises repeating units of d-N -acetyl glucosamine and
d-glucuronic acid. HA is often confined to specific areas within
tissues, for example, HA is present around blood vessels and bron-
chioles in the lung (3). At homeostasis, HA production is balanced
by its cellular uptake and degradation (4). Cellular HA synthases
(HAS 1–3) and hyaluronidases (Hyal 1–3) mediate the turnover
of HA [reviewed in more detail elsewhere (5–11)]. HA catabo-
lism can occur locally by nearby cells involving CD44-mediated
uptake, partial degradation by Hyal 2, and further degradation in
the lysosome by Hyal 1 [(12, 13); see Figure 1]. Alternatively, HA
can drain into the lymphatics and be degraded at a distant site
such as the liver (2).
During inflammation, an increase in HA is accompanied by a
decrease in chain length, possibly due to altered HAS and Hyal
activities (3, 18) or to cleavage by reactive oxygen and nitrogen
species produced by activated immune cells (23, 24). Macrophages
are thought to be involved in HA uptake and the removal of HA
fragments (19), and stromal cells are a major source of newly syn-
thesized HA, see Figure 1. Upon the resolution of inflammation,
HA production and cellular turnover return to normal and the
high molecular mass form predominates again.
THE DIFFERENT FORMS OF HA
AT HOMEOSTASIS
HA as part of the extracellular matrix
Hyaluronan is secreted from the cell and forms pericellular or
extracellular matrices presumably after cleavage and release from
the cell surface. HA is a major component of the ECM and at
homeostasis, extracellular HA is found predominantly in its high
molecular mass form of over 1000 kDa (10, 25, 26). HA chains
occupy a large hydrodynamic volume in solution (27) and can
associate with collagen in extracellular matrices. Proteoglycans
such as versican and aggrecan bind to HA and this could create a
stable network under homeostatic conditions (14–16).
DURING INFLAMMATION
HA fragments
Both damage and inflammatory conditions can cause the frag-
mentation of HA, which is considered fragmented when its mol-
ecular mass falls below 500 kDa. Studies in the lung tissue have
reported the detection of 500 kDa HA fragments after bleomycin-
induced inflammation (19), 70 kDa fragments after cigarette
smoke-induced chronic obstructive pulmonary disease (COPD)
(18), and 100–200 kDa fragments in the bronchial alveolar lavage
fluid (BALF) after ozone-induced airway hyper-responsiveness
(20). There is evidence that HA fragmentation can result from
degradation by reactive oxygen species (ROS) that are produced
by neutrophils (23, 24), or by enzymatic cleavage by Hyal 1 or 2
that perhaps have escaped from dying cells. Hyal 2 and Hyal 1
both work optimally at acidic pH and break down HA to 20 kDa
and small oligomers, respectively (28). Alternatively, an increase in
HA fragments may be the result of HA synthases making smaller
chains of HA (3, 18).
FIGURE 1 | Model showing HA turnover at homeostasis and during
inflammation. At homeostasis (A), stromal cells produce ECM, including
HA, which becomes decorated with proteoglycans such as versican (14–16),
indicated by the yellow brush structures. HA is turned over in tissues, likely
by CD44-mediated cellular uptake by fibroblasts and macrophages (17),
then degraded by Hyal 1 and 2 (12, 13). (B) During inflammation, the levels
of HA increase and the ECM becomes susceptible to damage and
fragmentation (18–20). Inflammation induced HA binding proteins such as
TSG-6 bind and crosslink itself or the heavy chain of IαI (HC) to HA (21, 22)
and in some situations such as chronic inflammation, HA deposits may
develop (3, 18). CD44-mediated uptake of HA fragments by macrophages is
thought to play an important role in resolving inflammation (19).
HA oligomers
Under normal conditions, small oligomers of HA should only be
present in the lysosome as HA is degraded into tetrasaccharides
by Hyal 1. Hyal 1 has been reported in the serum, but neither the
source nor its activity is known (28). Thus, one can predict that
the smallest oligomers of HA would only be present under severe
inflammatory conditions when there is significant cell death and
release of the lysosomal contents. It is these smaller oligomers that
are thought to activate dendritic cells (29, 30). As CD44 binds
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to these oligomers with very low avidity, they may activate den-
dritic cells by interacting with other receptors such as TLR2 or 4,
although this remains to be shown directly.
HA complexes
In vitro, pericellular cable-like structures of HA can be induced
in cells in response to inflammatory stimuli such as polyI:C, a
viral RNA mimic (31, 32), or to tunicamycin, an ER stress and
N-glycosylation inhibitor (33). These HA cables are also posi-
tive for the inter-alpha-trypsin inhibitor (IαI) (32). The heavy
chains (HC or serum HA-associated protein, SHAP) of IαI can
become covalently bound to HA and this is thought to crosslink
and stabilize HA (34). The human monocytic cell line U937 and
human peripheral blood mononuclear leukocytes, which do not
bind soluble HA, can bind to these cables (31, 32, 35), although
only at 4°C as at 37°C the HA is taken up by the U937 cells.
(36). HA cables have been induced in a variety of cell types
in vitro, including smooth muscle cells from the lung (37) and
colon (32), in airway (38) and renal epithelial cells (39), as
well as epidermal keratinocytes (40). However, HA cables have
yet to be described in vivo, although HA and IαI co-staining
has been reported in a human case of inflammatory bowel
disease (32).
TNFα-stimulated gene-6 protein (TSG-6) is a multifunctional
protein that has a HA binding module and binds HA under
acidic conditions (41). TSG-6 production is greatly increased with
inflammation and is associated with tissue remodeling (41). TSG-
6 is the enzyme that catalyzes the covalent addition of the HC
from IαI to HA (21, 22, 42), which can lead to the crosslinking and
aggregation of HA (34). Interestingly, TSG-6 and the attachment
of the HC from IαI enhance the binding of HA to CD44 (43, 44).
Furthermore, these HA–HC complexes are found as HA deposits
in vivo during persistent inflammation in the lung and TSG-6
has been shown to promote these deposits (3, 45). However, the
function of these HA–HC complexes in inflammation and tissue
remodeling is still being explored.
HA BINDING BY IMMUNE CELLS AT HOMEOSTASIS
HA BINDING BY ALVEOLAR MACROPHAGES
Under homeostatic conditions, without infection or inflamma-
tion, the majority of developing and mature immune cells do not
bind HA, as assessed by flow cytometry using fluoresceinated HA
(Fl-HA, see Box 1). In fact, alveolar macrophages are the only
immune cells that have been shown to bind high levels of HA under
homeostatic, non-inflammatory conditions, in both rodents and
humans [(46–48); see Table 1]. Alveolar macrophages reside in
Box 1 Evaluation of HA binding by flow cytometry.
Hyaluronan from rooster comb (1000–1500 kDa) or commercially available HA of specific molecular mass is conjugated to fluorescent dyes,
using the method of de Belder (52), or indirectly using a coupling reagent. Fluoresceinated HA (Fl-HA) used in flow cytometry provides a use-
ful means to evaluate surface HA binding, HA uptake, and CD44-specific HA binding using HA-blocking CD44 mAbs such as KM81 or KM201
(53). To date, all experiments indicate that the HA binding on immune cells is mediated by CD44 [(54, 55), and reviewed in Ref. (56, 57)].
High molecular mass HA (>1000 kDa) binds to CD44 with a higher avidity than medium (~200 kDa) or low (<20 kDa) molecular mass HA
fragments, and thus high molecular mass Fl-HA is routinely used to evaluate HA binding by immune cells. CD44 can bind monovalently to
6–18 sugars of HA, with a noticeable increase in avidity when the HA reaches 20–38 sugars in length, suggesting that divalent binding is
occurring (58).The avidity will increase with increasing length as more CD44 molecules are engaged. Ultimately, the strength of Fl-HA bind-
ing depends on the size of HA as well as the amount, density, and type of CD44 at the cell surface. Flow cytometry allows us to determine
relative HA binding abilities as it can distinguish cells that bind different amounts of Fl-HA. The pretreatment of cells with hyaluronidase
(which is then washed away) can determine if CD44 is binding to endogenous HA and thus blocking the binding of Fl-HA. It is thus a useful
technique to gain insights into the HA binding abilities of CD44. Commercial sources now provide specific molecular sizes of purified soluble
HA that are low in contaminants and endotoxin. However, it is important to keep in mind that purified soluble chains of HA may not always
be the form encountered in vivo.
Table 1 | HA binding ability of immune cells.
Cell type Stimulation Type of HA binding HA receptor Reference
Monocyte (human) TNFα, LPS, IL-1, IFN-γ Inducible CD44 (59–61)
Alveolar macrophages (human, rodents) None Constitutive CD44 (17, 46–48, 50)
Peritoneal macrophage (mouse) LPS with IFNγ, or IL-4 Inducible CD44 (62)
Bone marrow-derived macrophages (mouse) LPS with IFNγ, TNFα, or IL-4 Inducible CD44 (62)
Monocyte-derived DC (human) CD40L expressing fibroblasts Inducible CD44 (63)
B cells (human, mouse) PMA, IL-5, LPS Inducible, a subset binds CD44 (64–67)
T cells (mouse) PMA/ionomycin, CD3 antibodies,
specific antigen, or superantigen
Inducible, often a subset
binds
CD44 (54, 55, 68)
CD4+ CD25+T regulatory cells (human and mouse) CD3+/−CD28 activation Inducible, a subset binds CD44 (69, 70)
Neutrophil (mouse) LPS induced liver inflammation
in vivo
Binding to SHAP
modified HA
CD44, not
RHAMM
(71)
NK cells (mouse) IL-2, IL-15 Inducible, a subset binds CD44 (72)
Platelets (mouse) None Constitutive CD44 (73)
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the respiratory tract and alveolar space, between the epithelial layer
and surfactant, where they are responsible for the uptake and clear-
ance of pathogens and debris. In the absence of these macrophages,
the immune response is exacerbated (49), indicating that these
scavenger cells also have a role in limiting inflammation, perhaps
by clearing debris and removing inflammatory stimuli. Alveolar
macrophages take up HA in a CD44-dependent manner, which is
then delivered to the lysosomes and subsequently degraded (17).
HA is present in the connective tissue space during lung develop-
ment, but is reduced as the number of CD44-positive macrophages
increases (50). Fetal alveolar type II pneumocytes produce HA
(51), which is thought to associate with the pulmonary surfactant.
However, in adults, it is less clear if mature pneumocytes make HA
and most of the HA in the lung tissue is found lining blood vessels
and bronchioles (3, 50). There seems to be two possible expla-
nations why alveolar macrophages constitutively bind HA: (1) to
bind to the HA producing pneumocytes to help anchor themselves
in the alveolar space or (2) to internalize HA or HA fragments and
help keep the alveolar space free of debris.
THE HA BINDING STATUS OF DENDRITIC CELLS
There is very little direct evidence that immature or mature den-
dritic cells bind HA, HA fragments, or oligomers of HA, despite
reports that HA fragments and small oligomers of HA stimu-
late dendritic cells to produce proinflammatory cytokines (29, 30,
74). Dendritic cells have been reported to express HA and HA-
synthesizing and degrading enzymes (75), with human monocyte-
derived dendritic cells expressing primarily HAS 3 (76). However,
it is not clear whether CD44 on either immature or activated den-
dritic cells is capable of interacting with HA. Unlike macrophages,
which stay in the tissues to fight infection and maintain homeosta-
sis, activated dendritic cells migrate to the draining lymph node,
where they present antigen to naïve T cells. A HA binding pep-
tide, Pep-1, reduced dendritic cell clusters and antigen-induced T
cell proliferation, however, Pep-1 acted on the T cells, suggesting
that T cells make HA (75). Non-endotoxin tested HA upregu-
lated costimulatory molecule expression on bone marrow-derived
dendritic cells, which facilitated T cell proliferation, while CD44
on the T cells promoted clustering with the dendritic cells (74).
However, since endotoxin is a common contaminant in some
HA preparations and can have similar effects on dendritic cells,
additional steps are needed to exclude an endotoxin effect. Super-
natants from Th1 clones also promoted HA-dependent adhesion
between human monocyte-derived dendritic cells and activated T
cells or Th1 or Th2 clones, providing evidence for a dendritic cell-
HA:CD44-T cell interaction (76). However, as we discuss below,
naïve T cells express low levels of CD44 and have a low avidity
for HA, making this mechanism unlikely to play a key role in
the initial contact and activation of naïve T cells, unless dendritic
cells produce a form of HA that enables naive T cells to bind. It
could, however, play a role in activating memory T cells, which
express higher levels of CD44 and have a greater propensity to
bind HA (54).
THE LACK OF HA BINDING BY NAÏVE T CELLS
Activated dendritic cells present antigen to naive T cells, which
stimulates their activation, proliferation, and differentiation into
effector T cells. Early studies showed that CD44 monoclonal
antibodies (mAbs) could provide a costimulatory signal that
together with a signal from the T cell receptor (TCR) activates
T cells (77–79). As CD44 is present in lipid rafts along with the
tyrosine kinase Lck (80), its crosslinking was thought to help Lck
activation and bring it into contact with the TCR signaling com-
plex (81). Although these antibodies crosslink CD44 and enhance
TCR signaling, there is limited evidence that HA can do this, per-
haps because naïve T cells have a very low avidity for HA. Data
from naïve T cells isolated from C57Bl/6 mice show that naïve T
cells express low levels of CD44 and do not bind Fl-HA (54, 55,
68). However, one study showed that immobilized HA could aug-
ment PMA or CD3-induced proliferation of human peripheral
blood T lymphocytes and could augment IL-2 production from
CD3-stimulated CD4 T cell clones (82). In this study, HA binding
did not become apparent until 1–2 days after stimulation.
HA BINDING BY IMMUNE CELLS DURING INFLAMMATION
Activation of immune cells by proinflammatory cytokines, inflam-
matory stimuli, and by antigen recognition can all induce HA
binding by CD44 [reviewed in Ref. (56); see Table 1]. HA bind-
ing in response to these stimuli is generally accompanied by an
increase in CD44 expression and typically takes 2–3 days to reach
maximal HA binding levels. Flow cytometry can indicate a shift
in HA binding or identify a specific subset of binding cells (see
Box 1 for more details). Table 1 shows the stimuli that induce HA
binding in the various immune cells. Although neutrophils are
major inflammatory phagocytic cells, these cells do not bind Fl-HA
and are normally recruited to inflammatory sites independently of
CD44 (83). However, as we discuss later, HC-modified HA pro-
vides a means of neutrophil recruitment to inflamed liver (71).
Below, we will focus on the HA binding abilities of monocytes,
macrophages, dendritic cells, and T cells during inflammation.
THE INDUCTION OF HA BINDING BYMONOCYTES ANDMACROPHAGES
Human monocytes in the blood bind negligible amounts of soluble
Fl-HA (59–61), but are induced to bind over a period of 2–3 days
when activated in vitro by inflammatory cytokines such as TNFα
and IL-1β, and the inflammatory agent, LPS (see Table 1). Simi-
larly, M-CSF-induced mouse bone marrow-derived macrophages
and ex vivo peritoneal macrophages do not bind Fl-HA until
induced by proinflammatory agents (62). Treatment of TNFα-
induced human monocytes with IL-4 prevents the induction of
HA binding (60), whereas IL-4 treatment alone induced HA bind-
ing on mouse bone marrow-derived macrophages (62). Both the
transcription and post-translational modifications of CD44, such
as glycosaminoglycan or carbohydrate addition, can influence
HA binding. Decreases in sialylation and changes in the chon-
droitin sulfate modification to CD44 can modulate HA binding
by human monocytes (84) and mouse macrophages, respectively
(62). Macrophages are found in many locations in the body, with
resident populations in the spleen, liver, skin, gut, lung and the
alveolar space, brain, and the peritoneum, but only the alveolar
macrophages bind substantial amounts of HA under homeostatic
conditions. This suggests that the environment of the macrophage
influences its ability to interact with HA, and raises the possi-
bility that these macrophages may be induced to bind HA when
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the environment or cytokine milieu changes upon infection or
inflammation.
Why inflammation induces HA binding on monocytes and
macrophages is not well understood. Possible explanations
include: (1) activated monocytes and macrophages use HA as
a substrate to aid in migration toward the site of infection; (2)
an enhanced ability to bind HA or HA–HC complexes to retain
activated immune cells in the tissue at sites of inflammation; (3)
an enhanced ability to bind, take up, and degrade HA, HA frag-
ments, or HA–HC complexes via CD44, thereby helping reduce
inflammation and promote tissue repair; (4) HA binding pro-
vides a supportive environment for these cells, either by providing
a direct survival signal to the cell or by creating a cytokine-rich
environment that aids in their survival, proliferation, or function.
HA BINDING BY ACTIVATED T CELLS
In contrast to unstimulated naïve T cells, antigen-induced activa-
tion of T cells induces HA binding, coincident with an increase
in CD44 expression, and this is now well-established both in vitro
and in vivo [(54, 55, 68); see Figure 2]. In vitro, the induction of
HA binding is transient, peaking at 2–3 days, whereas it is more
sustained in vivo, reaching its maximum around 5–8 days (54, 55).
The absence of any significant Fl-HA binding on naïve T cells until
2–3 days, after at least the first division, also argues against a model
where HA on dendritic cells facilitates CD44-mediated naïve T cell
adhesion and the initiation of T cell activation. As T cell activa-
tion and proliferation proceeds, HA binding increases, as does the
ability of T cells to roll under flow on a HA substrate (85) and
the ability of superantigen-activated T cells to extravasate to the
inflamed peritoneum in an HA-dependent manner (86). Thus,
one function of the upregulation of HA binding by activated T
cells may be to guide the effector T cell to the site of infection. This
later induction of HA binding after activation and some prolifera-
tion suggests a role beyond the initial contact and activation step.
Notably, the strength of the signal received by the T cell dictates
the level and percentage of T cells that are induced to bind HA,
with cells binding the most HA being the most proliferative (54).
Despite these correlations, no evidence was found to support HA-
stimulated proliferation. However, in another study focusing on
CD4+ CD25+ T cells, HA was found to stimulate IL-2 production
and sustain FoxP3 expression (87). 4-methylumbelliferone, a com-
pound that can inhibit HA synthesis (88, and also see article in this
research topic), prevented T cell proliferation and IL-2 production,
suggesting that HA synthesis by the T cell itself is important for
this effect (89). Thus, there is some evidence that HA produc-
tion and/or the binding of high molecular mass HA on activated
T cells may enhance IL-2 production, which may either prolong
T cell proliferation or, if acting on regulatory T cells (Tregs), may
limit T cell activation. The outcome of an interaction of activated
T cells with high molecular mass HA may also depend on the
differentiation state of the T cell, as re-activated T cells exposed
to high molecular mass HA undergo a rapid form of activation-
induced cell death, as observed in human Jurkat T cells and a
subpopulation of splenic T cells from mice (90).
HA BINDING BY EFFECTOR CD4 AND CD8 T CELLS
After naïve T cell activation and proliferation, CD4 T cells differ-
entiate into various effector T cells (Th1, Th2, Th17, Tregs), and
CD8 T cells become cytotoxic effector cells. Both CD4 and CD8
effector cells leave the lymph node and migrate to the infected tis-
sue to fight the infection. After the initial induction of HA binding
during the proliferative phase, it is less clear how long these cells
retain their HA binding abilities. In vitro evidence indicates that
after antigen-induced HA binding in 50% of ovalbumin- (Ova-)
specific OT-I CD8 T cells 2 days post activation, only 6% retain
HA binding at day 6 (54). In vivo, antigen-induced HA binding
peaks 5 days post infection, marking approximately 50% of the
OT-I CD8 T cells, and this drops to 14% by day 10, indicating that
HA binding is more sustained in vivo although it also declines after
the peak of the proliferative phase (54). In other mouse studies, the
percent of HA binding cells peaked at day 7–8 and the HA-positive
population contained the majority of the cytotoxic CD8 T effector
cells (55), consistent with the HA-negative cells being naïve cells.
However, since both soluble HA and HA-blocking CD44 mAbs
had no effect on allogeneic killing, HA binding was not impli-
cated in the killing function of these cells (55). After the peak
of the response, many effector T cells undergo apoptosis during
the contraction phase and only long-lived memory cells remain.
FIGURE 2 |Timeline of theT cell response and HA binding.
Before immune challenge, naïve T cells express low levels of CD44
and have low affinity/avidity for HA (55). Following activation, HA
binding is induced (55, 68) and marks the most proliferative,
activated T cells (54). HA binding on effector T cells has a role in
T cell extravasation into inflamed peritoneum (68), and marks the
majority of cytotoxic CD8 T cells (55). Contraction and generation of
memory CD8 T cells result in memory cells that maintain high levels
of expression of CD44 but only a percentage of them
(approximately 30%) bind HA (54).
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Following Listeria-Ova infection and the development of T mem-
ory cells in vivo, about 30% of the Ova-specific OT-I CD8 memory
T cells in the bone marrow and spleen bind Fl-HA 30 days after
infection [(54); see Figure 2].
CD4 T cells differentiated in vitro to become either Th1 or Th2
bind slightly higher levels of Fl-HA than naïve T cells, with Th2
cells binding slightly more than Th1, but the binding is still at a very
low level (91, 92). Nevertheless, this low-level binding is sufficient
to allow them to roll and adhere on TNFα-inflamed endothe-
lium in vivo (91). In another study, CD44 promoted T effector
cell survival from Fas-mediated contraction, and was required for
the formation of Th1 memory cells, but the effect of HA was not
examined (93). Thus HA binding by effector T cells may assist
in their recruitment to inflammatory sites and the interaction of
HA with CD44 in the tissues may provide a survival signal for the
effector T cell.
HA BINDING BY ACTIVATED CD4 T REGULATORY CELLS
Tregs express CD4 and CD25, as do activated CD4 T cells, and so
are further characterized by expression of the transcription factor,
FoxP3 (94). Firan and colleagues activated CD4+CD25+ T cells
isolated from BalbC mice, separated them into HA binding and
non-binding populations, and found that the HA binding frac-
tion was functionally more suppressive (69). The activation of
human peripheral blood CD4+CD25+ T cells induced a subpop-
ulation to bind HA and this correlated with the highest expression
of CD44 and FoxP3 (70). The addition of 20µg/ml of high
molecular mass HA (1.5× 106 Da) maintained FoxP3 expression
under limiting levels of IL-2, and enhanced their suppressive abil-
ity in vitro. At a higher concentration (100µg/ml), HA directly
reduced CD4 T cell proliferation (70). Both high molecular mass
HA and the crosslinking of CD44 provided a costimulatory signal
that augmented IL-2, FoxP3 expression, and IL-10 production in
the human CD4+ CD25+ T cell population (87). Furthermore,
HA or CD44 crosslinking activated p38 and ERK1/2-dependent
pathways that induced IL-10 producing regulatory T cells (TR1)
from FoxP3-negative cells (95). Together, this suggests a role for
high molecular mass HA in limiting T cell proliferation either
indirectly via supporting Tregs or directly when given in higher
amounts to CD4 T cells.
It is clear from the above sections that HA binding by T cells is
not restricted to activated Tregs, suggesting a more general func-
tion for HA binding in activated CD4 and CD8 T cells. Since HA
binding labels the most proliferative, functionally active T cells,
HA may exert its effect by aiding in the production of IL-2 under
limiting conditions. Alternatively, perhaps HA localizes activated
T cells to a specific area in the lymph node, where they have opti-
mal access to cytokines and growth factors, or maybe HA binding
itself provides a survival signal for activated T cells.
THE FUNCTION OF HA BINDING BY IMMUNE CELLS
Previous reviews have discussed HA binding by immune cells (56,
85), and have detailed what is known regarding the role of HA (96)
and CD44 in inflammation and inflammatory diseases (57, 97,
98). Many diseases involve an inflammatory component and it has
become apparent that HA levels are increased in many tissues upon
inflammation. Here, we describe the effects of HA interactions
with immune cells during inflammation with a particular focus
on lung inflammation.
THE ROLE OF CD44 AND HA IN LEUKOCYTE RECRUITMENT TO
INFLAMMATORY SITES
Upregulation of HA on microvascular endothelium facilitates T cell
recruitment
At the first signs of damage or infection in a tissue, ensuing danger
signals are received by macrophages that induce the secretion of
inflammatory stimuli such as TNFα and IL-1β, which act on the
endothelium in the microvasculature. This leads to the upregula-
tion of adhesion molecules that facilitate leukocyte recruitment to
the inflamed tissue. HA is one adhesion molecule that is upreg-
ulated on microvascular endothelial cell lines (99). Under flow
conditions, T cells can roll on HA via CD44 both in vitro (100,
101) and in vivo (91), implying that the upregulation of HA
on activated endothelial cells will facilitate T cell recruitment to
inflamed tissues. Indeed, a CD44-mediated interaction with HA
is important for T cell extravasation into the peritoneum in a
model of superantigen-driven T cell activation and inflammation
(86). However, given the well-established roles of the selectin mol-
ecules in leukocyte recruitment (102), the CD44–HA interaction
may provide an additional and possibly redundant mechanism to
facilitate T cell extravasation. The fact that the majority of CD44-
deficient leukocytes still reach inflammatory sites (57) supports
this idea.
HC-modified HA facilitates CD44-mediated neutrophil recruitment to
liver sinusoids
CD44- and HA-dependent rolling on endothelium is not a factor
for neutrophil recruitment to inflammatory sites (83). However,
CD44-mediated adhesion to HA is a key factor in neutrophil
adhesion to inflamed liver sinusoids in endotoxemic mice (71).
Leukocyte recruitment to liver sinusoids proceeds in the absence
of rolling and involves both integrin- and CD44-dependent mech-
anisms (103). LPS recognition by liver endothelial cells induces the
deposition of HC (SHAP) on HA that is constitutively expressed
by the liver sinusoids, and this leads to CD44-dependent adhesion
of neutrophils to HA (71, 104, and also see article in this research
topic).
CD44-mediated HA binding facilitates eosinophil and Th2 cell
recruitment to the allergic lung
In experimental pulmonary eosinophilia that is induced by admin-
istration of Ascaris suum extract, HA-blocking CD44 antibodies
prevented lymphocyte and eosinophil recruitment into the BALF
(105). A follow-up study using CD44-deficient mice and the house
dust mite allergen concluded that the loss of CD44 affected Th2,
but not Th1 recruitment to the BALF (92). This suggests that HA
and CD44 play a role in the recruitment of eosinophils and Th2
cells in an allergic response in the lung.
A ROLE FOR HA FRAGMENTS AND DEPOSITS IN PROMOTING
INFLAMMATION
The proinflammatory effects of HA fragments on immune cells
In vitro. Hyaluronan fragments were first reported to stimu-
late chemokine and proinflammatory cytokine expression and
NFkB-mediated iNOS expression in macrophage cell lines in the
Frontiers in Immunology | Inflammation April 2015 | Volume 6 | Article 150 | 6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lee-Sayer et al. Hyaluronan binding by immune cells
1990s (106–109). At first, it was thought that CD44 mediated
the effect of these HA fragments, which were quite large (470,
200–280 kDa), but later studies began to implicate the toll-like
receptors, TLR2 and/or TLR4 (Table 2; Figure 3). While CD44
can bind HA fragments on activated cells, it is not clear if this
alone leads to proinflammatory cytokine secretion. Instead, TLR4
(110), TLR2 (111), TLR2 and TLR4 (112), a complex of CD44 and
TLR4 (113), or a combination of TLR4, CD44 and activation of the
NLRP3-mediated inflammasome (114) have all been implicated
in mediating HA fragment-induced proinflammatory signals (see
Figure 3). TLR4 was required for HA oligomers to initiate den-
dritic cell maturation and proinflammatory cytokine production
from both human and mouse in vitro-derived dendritic cells (29,
30) and 200 kDa HA fragments stimulated dendritic cell matura-
tion in a CD44-independent manner (74). However, whether HA
fragments can directly activate TLRs remains uncertain, as cont-
aminants such as LPS can produce similar results and the direct
binding of HA to TLRs has not yet been demonstrated. This needs
to be determined to establish HA as a bone fide TLR ligand.
In Table 2, we summarize the reported proinflammatory effects
of HA and HA fragments on macrophages and dendritic cells
in vitro. Proinflammatory effects have been reported with a wide
range of HA fragment sizes: from HA oligomers [2–18 mers] to
HA fragments ranging from 5 to 500 kDa. Interestingly, we note
that HA fragments derived from rooster comb did not generally
elicit proinflammatory responses whereas human umbilical cord-
derived HA did. Human umbilical cord HA is not as pure as HA
purified from rooster comb (some preparations are FDA approved
for injection into humans), leaving open the possibility that the
effects seen with human umbilical cord HA maybe due to LPS con-
tamination. Indeed, in our hands HA from human umbilical cord
but not rooster comb, tested positive for endotoxin (unpublished
data). Although endotoxin levels were checked and polymyxin B
was added to bind to LPS in some cases, possible residual contam-
ination with TLR agonists remains a concern. In some cases, DNA
contamination of HA was responsible for the proinflammatory
activity on monocytes (119). Alternatively, there could be some-
thing different about the HA isolated from human umbilical cord
as it does appear to be of a lower average molecular mass compared
to rooster comb HA. Specific sizes of HA are now available from
commercial sources that are purified from bacteria and certified
endotoxin-free, and so it will be of interest to see if similar data are
obtained with these HA preparations. Indeed, studies monitoring
endotoxin levels more closely are now emerging. One report on
glomerular mesangial cells shows that hyaluronidase is contami-
nated with LPS and suggests that HA provides a protective barrier
for cells, which when cleaved exposes the TLRs (120). Others
report no proinflammatory effect of endotoxin-free HA oligomers
(118) or HA fragments on immune cells [(117); see Table 2].
Thus, further work with endotoxin-free HA is needed to sub-
stantiate whether HA fragments induce proinflammatory cytokine
production and whether they do this by directly engaging TLRs.
In vivo. Ozone-induced airway hypersensitivity is associated
with increased hyaluronan in the BALF, and CD44- and IαI-
deficient mice were protected from this airway hypersensitivity
implying a role for CD44 and IαI in driving the hypersensitivity
(20). Interestingly, the instillation of fragmented, but not full-
length HA, partially mimicked airway hyper-responsiveness (20).
Ozone- and fragmented HA-induced airway hyper-responsiveness
were also reduced in TLR4- and MyD88-deficient mice, leading
to the conclusion that fragmented HA responses require TLR4
in vivo (121).
Using a mouse model of allergic contact dermatitis, Martin
and colleagues found that inhibition of ROS and HA breakdown
prevented sensitization and contact hypersensitivity (118). ROS
stimulated hyaluronidase activity, which rapidly degraded HA
in the epidermis, in a similar mechanism to that described in
bronchial epithelial cells (122). Although this in vivo hypersen-
sitivity reaction requires TLR2 and TLR4 (123), the authors have
been unable to activate dendritic cells in vitro using commercially
available HA oligomers of 2–12 sugars in length (118). These stud-
ies show that HA fragmentation occurs in vivo and is required for
hypersensitivity responses, as are TLRs. If HA fragments do not
act directly via the TLRs, perhaps TLRs are activated indirectly, by
something that is released or produced upon their fragmentation.
The involvement of IαI suggests that in vivo HA fragments may
arise from HA–HC deposits and thus may contain other proteins
and proteoglycans besides HA. This also raises the cautionary note
that HA fragments and HA–HC complexes generated in vivo may
be quite different from the purified forms of HA used in vitro
studies and in Fl-HA labeling. Further work is thus needed to
understand the HA-driven inflammatory mechanisms observed
in vitro and in vivo.
HA deposits promote an allergic inflammatory response in the lung
In a mouse model of allergic asthma using Ova, a significant
increase in HA deposition is observed in lung tissue (3). This
was attributed to early increases in HAS 1 and HAS 2 mRNA
expression and a decrease in Hyal 1 and Hyal 2 expression in
the lung tissue (3). HA deposits provided sites for inflammatory
cells to accumulate and supported subsequent collagen deposition
(3). TSG-6 promoted HA deposition, suggesting the formation
of HA–HC complexes, and eosinophilic airway inflammation and
airway hyper-responsiveness (45), correlating HA deposits with
the eosinophilic response. Further evidence for a role of HA in
allergic airway inflammation comes from the use of a HA syn-
thesis inhibitor, 4-methylumbelliferone (88), which reduces Ova-
induced eosinophil airway inflammation (124). Thus, these HA
deposits may support inflammation by sequestering inflammatory
cells and providing survival or other signals. Alternatively, it is pos-
sible that the presence of HA deposits may reflect an attempt to
resolve the inflammation by promoting matrix deposition. More
work is needed to fully understand the role of HA deposits in the
inflammatory response.
A ROLE FOR CD44 IN RESOLVING INFLAMMATION
CD44 facilitates the clearance of HA fragments and helps resolve
sterile inflammation in the lung
The mouse bleomycin model of sterile inflammation and fibro-
sis has been used extensively by Noble and colleagues, and has
provided key data on the role of HA and CD44 in the inflamma-
tory process [reviewed in Ref. (97, 112)]. Bleomycin induces lung
injury and necrosis that triggers an inflammatory response and
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Table 2 |The effect of HA and HA fragments on macrophages and dendritic cells.
Cell type HA size (kDa) HA source Effect Molecule Steps to exclude LPS Reference
MACROPHAGES AND MONOCYTES
BMDM 40–80 Bovine trachea Induced IL-1β, TNFα mRNA CD44 Used LPS hyporesponsive mouse (106)
BMDM and
MH-S cell line
6000 Rooster comb No effect – Not specified (107)
474, 267 Sonicated Activated NFκβ
MH-S cell line
and human
inflammatory
alveolar Mφ
6000 Rooster comb No effect CD44 Endotoxin tested, polymyxin
added
(109)
470 Sonicated Induced MIP1α, MIP1β, IP-10,
RANTES, MCP-1 mRNA in
mouse and IL-8 in human
280 Human umbilical
cord35
6 mer Rooster comb
2 mer Not specified No effect
MH-S cell line,
BMDM
200 Human umbilical
cord
Induced iNOS mRNA Used LPS hyporesponsive mouse,
polymyxin added
(108)
Activated NFκβ
Elicited
peritoneal Mφ
280 Human umbilical
cord
MIP1α, MIP1β, RANTES, IL-12
mRNA
Used LPS hyporesponsive mouse,
endotoxin present, polymyxin
added
(115)
Peritoneal Mφ 135 Digested from
bacterial HA
Induced MIP-2 and TNFα TLR2 CD44, TLR2/4 KO mice. Endotoxin
tested (<40 pg/mg HA), Hyal
digestion, polymyxin added
(112)
TLR4
200 Patient seruma Induced MIP-2, MIP1α, KC Not CD44
Elicited
peritoneal Mφ
6000 Rooster comb No effect – Used LPS hyporesponsive mouse,
endotoxin tested solutions,
polymyxin added
(111)
200 Human umbilical
cord
Induced MIP1α, MIP1β, KC,
MCP-1, RANTES,TNFα mRNA
TLR2
MH-S cell line
and human
THP-1 cell line
Not specified Human umbilical
cord
Induced MIP-2, TNF α,
GM-csf, RANTES IL-1α, and
Mmp13, Tgfb2 mRNA, and
IL-8 (human)
CD44 Endotoxin removed, DNA free (113)
TLR4
MH-S cell line
and elicited
peritoneal Mφ
200 Human umbilical
cord
Induced TNFα and KC
secretion
– Used LPS hyporesponsive mouse (116)
MH-S cell line
and elicited
peritoneal Mφ
500–730 Rooster comb No effect CD44 Used a LPS hyporesponsive
mouse, Hyal digestion, endotoxin
removal
(114)
Up to 500 Human umbilical
cord
Induced MIP-2 and pro-IL-1β
via TLR4. Induced IL-1β via
CD44, Hyals and NLRP3
TLR4
NLRP3
4–18 mers Not specified Induced MIP-2
Raw264 and
MH-S cell line
Specific sizes
11–970
Acid hydrolysis of
bacterial HA
No effect on NO or TNFα – Endotoxin tested <0.01 EU/ml (117)
DENDRITIC CELLS
BMDC, human
blood-derived
DCs
1000 Rooster comb,
sonicated
No effect – Endotoxin tested (<0.06 EU/ml or
<0.1 ng/ml LPS), polymyxin added
(29, 30)
80–200
4–14 mers Hyal digestion of
sonicated HA
Induced HLR-DR expression
and IL-1β, TNFα, IL-12.
Activated NFκβ. Activated
MAPK/p38 and NFκβ
TLR4 not
CD44 or
RHAMM
BMDC >570 Not specified Upregulated CD40, CD80,
CD86
Not CD44 Polymyxin added (74)
BMDC 200 Human umbilical
cord
Induced MIP1α Used LPS hyporesponsive mouse,
polymyxin added
(111)
BMDC 2–12 mers Commercial
source
Unable to activate DCs in vitro – – (118)
All cells are murine unless otherwise stated.
BMDM and BMDC, bone marrow-derived macrophages and dendritic cells, respectively; Mφ, macrophages; Hyal, hyaluronidase. MIP-2 and KC are also known as
CXCL2 and CXCL1, respectively.
aPatient serum was from patients with acute lung injury. Items in blue indicate no proinflammatory effect was observed with HA.
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FIGURE 3 |The various receptors implicated in mediating the
proinflammatory signals induced by HA fragments. From the left, HA
fragments ranging from 500 kDa and below have been reported to stimulate
proinflammatory cytokine production via TLR4 alone, TLR2 alone, both TLR2
and TLR4, a complex of TLR4 involving CD44, or via TLR4- and CD44-mediated
uptake that leads to inflammasome activation (110–114). In the first three
panels, the TLRs signal via MyD88 to activate NF-κB and induce
proinflammatory cytokine gene expression. In the fourth panel, CD44,
together with TLR4 and MD-2, is needed for HA-stimulated proinflammatory
cytokine production. In the fifth panel, TLR4 signals via MyD88 to produce
pro-IL-1β and the uptake of HA via CD44 leads to the breakdown of HA which,
through some unknown mechanism, leads to HA oligomers in the cytoplasm
and these trigger NLRP3 inflammasome activation. This leads to cleavage of
pro-IL-1β and the generation of IL-1β (114).
subsequent wound repair mechanisms. Inflammatory monocytes
and neutrophils are recruited to the damaged site, where they are
activated by inflammatory signals released from the injured and
necrotic tissue. These activated cells will phagocytose cell debris
but will also produce anti-microbial factors such as ROS, which
cause further tissue damage. HA is normally undetectable in the
BALF but increases upon inflammation to approximately 2µg/ml
at the peak of the response. HA levels are also increased in the
lung tissue upon inflammation, from 100 to 300 ng/mg of dry
tissue. This increase is also accompanied by a decrease in mole-
cular mass (500 kDa compared to the normal size of 1400 kDa)
(19). Normally, the inflammatory response transitions to a heal-
ing response, where further neutrophil recruitment is halted, and
debris and apoptotic neutrophils are scavenged by macrophages
and/or inflammatory monocytes. Increased levels of TGFβ stimu-
late fibroblast proliferation and ECM production, which restores
the tissue back to its original state. In CD44-deficient mice, the
initial inflammatory phase appears normal, except for a higher
accumulation of HA fragments. However, the CD44-deficient mice
cannot resolve the inflammation: TGFβ activation is defective;
apoptotic neutrophils are not cleared; and HA levels continue to
rise in both the BALF and lung tissue (19). This points to a defect
in clearance by macrophages or monocytes and a role for CD44
in this process. This defect is largely corrected by reconstitution
of CD44-deficient mice with a CD44-sufficient immune system
(19), further implicating CD44 on immune cells in the clearance
of HA. The CD44-mediated uptake of HA and associated debris,
together with CD44-assisted activation of TGFβ (125), may be
sufficient to tip the balance toward the resolution phase of the
inflammatory response. While a protective role for CD44 has also
been observed in severe hypoxia-induced lung damage by promot-
ing HA clearance and protecting from epithelial cell death (126),
this role for CD44 in the resolution phase is not universally appar-
ent, particularly when infections occur. This highlights potential
differences between pathogenic and sterile inflammation and/or
suggests that additional factors drive resolution when pathogens
are encountered.
SUMMARY
The key points to emerge from this review are:
1. Few immune cells bind HA during homeostasis (alveolar
macrophages are a notable exception).
2. The form of HA (its size, association with other molecules, and
its ability to form complexes) changes between homeostasis
and inflammation.
3. Immune cell interactions with HA increase upon an inflamma-
tory response. This may help recruit immune cells to the site of
inflammation as well as keep cells at the site and may facilitate
their survival and function.
4. CD44 is the only receptor that has been demonstrated to bind
HA on immune cells. HA binding by CD44 can lead to HA
uptake and its subsequent degradation. Macrophage CD44
is thought to play an important role in HA uptake and the
clearance of HA fragments during lung inflammation.
5. Additional evidence is required to establish whether purified
HA fragments and HA oligomers are proinflammatory and if
so, what receptors do they interact with to mediate this effect.
6. There is a need to better understand the composition and struc-
ture of the HA fragments and complexes present in vivo during
an inflammatory response, and to then mimic their effects
in vitro.
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